Reply to Caccialanza et al.

Pierre Boisselier (1) , Simon Thézénas (1) , Nicolas Flori (1) , Marie Vinches (1) , Jean Bourhis (2) , Pierre Senesse (1, 3)

1 ICM - Institut régional de Cancérologie de Montpellier
2 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
3 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier

A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX. Boisselier P, Kaminsky MC, Thézenas S, Gallocher O, Lavau-Denes S, Garcia-Ramirez M, Alfonsi M, Cupissol D, de Forges H, Janiszewski C, Geoffrois L, Sire C, Senesse P; Head and Neck Oncology and Radiotherapy Group (GORTEC). Am J Clin Nutr. 2020 Dec 10;112(6):1523-1531. doi: 10.1093/ajcn/nqaa227. PMID: 32936874 Clinical Trial. Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. Caccialanza R, Cereda E, Orlandi E, Filippi AR, Comoli P, Alberti A, Imarisio I, Pedrazzoli P, Bossi P. Am J Clin Nutr. 2021 Apr 6;113(4):1053-1054. doi: 10.1093/ajcn/nqaa421. PMID: 33822867 No abstract available.

Domaines: Sciences du Vivant [q-bio]

Pierre Boisselier, Simon Thézénas, Nicolas Flori, Marie Vinches, Jean Bourhis, et al.. Reply to Caccialanza et al.. The American Journal of Clinical Nutrition, 2021, 113 (4), pp.1054-1055. ⟨10.1093/ajcn/nqaa425⟩. ⟨hal-03706033⟩